{"id":71388,"date":"2026-05-20T08:30:59","date_gmt":"2026-05-20T08:30:59","guid":{"rendered":"https:\/\/medsbase.com\/ara-290\/"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"ara-290","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-pt\/product\/ara-290\/","title":{"rendered":"ARA-290 (Cibinetide)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 ARA-290?<\/h3>\n<p style=\"margin: 0;\"><strong>ARA-290<\/strong> (cibinetide; Helix B Surface Peptide, HBSP) is an 11-amino-acid synthetic peptide derived from helix B of erythropoietin (EPO). Designed by Brines &amp; Cerami to dissociate EPO&#8217;s cytoprotective effects from its erythropoietic effects, ARA-290 binds the innate repair receptor (IRR) \u2014 a heterocomplex of the EPO receptor and the beta-common receptor (CD131) \u2014 and triggers anti-inflammatory, anti-apoptotic, and tissue-repair signalling without elevating red-cell mass. Developed by Araim Pharmaceuticals; orphan-designated for sarcoidosis-associated small-fiber neuropathy. Supplied in 10 mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-pt\/reviews\/\">de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada encomenda est\u00e1 coberta pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Garantia de Reenvio<\/strong><\/a> \u2014 se a sua encomenda n\u00e3o chegar no prazo de 20 dias \u00fateis, reenviamo-la.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1208243-50-8 (cibinetide)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00e9ptido sint\u00e9tico de 11 amino\u00e1cidos n\u00e3o eritropo\u00e9tico derivado da h\u00e9lice B da eritropoetina humana (Helix B Surface Peptide, HBSP); agonista do receptor de repara\u00e7\u00e3o inata (IRR); c\u00f3digos de desenvolvimento ARA-290 \/ cibinetida (Araim Pharmaceuticals)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>51<\/sub>H<sub>84<\/sub>N<sub>16<\/sub>O<sub>21<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~1,257.4 Da<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">H-pyroGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH (pyrEEQLERALNSS) \u2014 sequ\u00eancia linear de 11 res\u00edduos correspondente \u00e0 face exposta \u00e0 \u00e1gua da h\u00e9lice B da eritropoetina humana. A glutamina N-terminal cicliza espontaneamente em piroglutamato (consistente com o MW publicado de 1,257.4 Da). O C-terminal \u00e9 um \u00e1cido livre; sem ponte dissulfeto, sem acila\u00e7\u00e3o com \u00e1cido gordo, sem PEGila\u00e7\u00e3o.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00f3 liofilizado (branco a branco sujo)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC verificado, COA dispon\u00edvel mediante pedido)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (frigor\u00edfico) para estoque de trabalho; \u221220 \u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos. Reconstitu\u00eddo: 2\u20138 \u00b0C, utilizar dentro de ~14\u201328 dias. Proteger da luz. Evitar ciclos repetidos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o da solu\u00e7\u00e3o reconstitu\u00edda.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u00c1gua bacteriost\u00e1tica (recomendada) ou \u00e1gua est\u00e9ril. Altamente sol\u00favel; o 11-mer n\u00e3o modificado dissolve-se rapidamente com agita\u00e7\u00e3o suave.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O que \u00e9 ARA-290?<\/h2>\n<p><strong>ARA-290<\/strong> (cibinetida) \u00e9 um p\u00e9ptido sint\u00e9tico linear de 11 amino\u00e1cidos correspondente \u00e0 face exposta \u00e0 \u00e1gua da h\u00e9lice B da eritropoetina humana (EPO) \u2014 uma regi\u00e3o da mol\u00e9cula de EPO que n\u00e3o est\u00e1 envolvida na liga\u00e7\u00e3o ao receptor cl\u00e1ssico homodim\u00e9rico de EPO (EPOR<sub>2<\/sub>) que impulsiona a produ\u00e7\u00e3o de gl\u00f3bulos vermelhos. ARA-290 foi racionalmente concebido por Michael Brines e Anthony Cerami na Araim Pharmaceuticals para dissociar duas atividades farmacologicamente distintas da EPO que historicamente estavam entrela\u00e7adas numa \u00fanica mol\u00e9cula: <strong>eritropoiese<\/strong> (o efeito de aumento do hemat\u00f3crito que limita o uso da EPO como agente protetor de tecidos devido ao risco tromboemb\u00f3lico) e <strong>prote\u00e7\u00e3o tecidual<\/strong> (the anti-inflammatory, anti-apoptotic, and repair-promoting effects mediated by a distinct heteromeric receptor). By restricting the peptide sequence to the helix-B surface face, ARA-290 retains affinity for the <strong>receptor de repara\u00e7\u00e3o inata (IRR)<\/strong> \u2014 um heterocomplexo composto pela subunidade do receptor de EPO (EPOR) e pelo receptor beta comum (\u03b2cR, CD131; a subunidade de sinaliza\u00e7\u00e3o partilhada dos receptores de GM-CSF, IL-3 e IL-5) \u2014 enquanto abole a liga\u00e7\u00e3o ao EPOR<sub>2<\/sub> homodimer responsible for erythropoiesis. The net effect is a peptide that produces EPO&#8217;s cytoprotective, anti-inflammatory, and neuroprotective effects in tissue without elevating hematocrit or carrying the thromboembolic and hypertensive risks that constrain therapeutic EPO use. ARA-290 has a short plasma half-life of approximately 2 minutes \u2014 the molecule is rapidly cleared \u2014 but the biological effect persists for 24\u201372 hours through downstream activation of cytoprotective signalling cascades (JAK2\/STAT3, PI3K\/Akt, anti-apoptotic Bcl-2 family upregulation). This pharmacokinetic profile is characteristic of receptor-trigger peptides where the duration of effect is driven by signal-cascade kinetics rather than by sustained plasma levels. ARA-290 has held <strong>designa\u00e7\u00e3o de medicamento \u00f3rf\u00e3o<\/strong> in the United States and the European Union for sarcoidosis-associated small-fiber neuropathy, and has been evaluated in multiple Phase 2 clinical trials in diabetic neuropathy and sarcoidosis-associated neuropathic pain. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Agonismo do Recetor de Repara\u00e7\u00e3o Inata Sem Eritropoiese<\/h2>\n<p>What makes ARA-290 pharmacologically distinctive is that it activates the cytoprotective limb of erythropoietin signalling while bypassing the erythropoietic limb. Three mechanisms are documented in published studies:<\/p>\n<ul>\n<li><strong>Agonismo do recetor de repara\u00e7\u00e3o inata (IRR) \u2014 EPOR + \u03b2cR \/ CD131 heterocomplexo<\/strong> \u2014 Em condi\u00e7\u00f5es inflamat\u00f3rias ou de les\u00e3o hip\u00f3xica, as c\u00e9lulas dos tecidos aumentam a express\u00e3o do recetor beta-comum (\u03b2cR, CD131) e montam um heterocomplexo com o recetor de EPO (EPOR). Este heterocomplexo IRR \u00e9 o alvo molecular do ARA-290. A liga\u00e7\u00e3o desencadeia a fosforila\u00e7\u00e3o de JAK2 e a ativa\u00e7\u00e3o descendente de STAT3 \/ STAT5 \/ PI3K-Akt, levando \u00e0 upregula\u00e7\u00e3o de prote\u00ednas anti-apopt\u00f3ticas (Bcl-2, Bcl-xL), supress\u00e3o da produ\u00e7\u00e3o de citocinas pr\u00f3-inflamat\u00f3rias (TNF-\u03b1, IL-1\u03b2, IL-6) e recrutamento de programas de repara\u00e7\u00e3o tecidual. Como o IRR \u00e9 upregulated localmente em locais de les\u00e3o ou inflama\u00e7\u00e3o em vez de ser expresso constitutivamente, o ARA-290 atua como um agonista restrito ao contexto que ativa a sinaliza\u00e7\u00e3o de repara\u00e7\u00e3o especificamente onde \u00e9 necess\u00e1rio.<\/li>\n<li><strong>Sem liga\u00e7\u00e3o ao EPOR homodim\u00e9rico<sub>2<\/sub> \u2014 sem eritropoiese<\/strong> \u2014 O recetor eritropoi\u00e9tico cl\u00e1ssico nos progenitores eritr\u00f3ides da medula \u00f3ssea \u00e9 um homod\u00edmero de duas subunidades EPOR sem envolvimento de CD131. O ARA-290 tem afinidade negligenci\u00e1vel por este homod\u00edmero, raz\u00e3o pela qual a administra\u00e7\u00e3o repetida em ensaios cl\u00ednicos n\u00e3o produz altera\u00e7\u00f5es detet\u00e1veis na hemoglobina, hemat\u00f3crito ou contagem de reticul\u00f3citos. Esta \u00e9 a caracter\u00edstica central de design que distingue o ARA-290 da EPO de comprimento total e dos an\u00e1logos de EPO anteriormente desenvolvidos (darbepoetina, CERA) que mantiveram atividade eritropoi\u00e9tica.<\/li>\n<li><strong>Efeitos anti-inflamat\u00f3rios e de repara\u00e7\u00e3o tecidual a jusante<\/strong> \u2014 In preclinical and clinical studies, ARA-290 reduces pro-inflammatory cytokine production by activated macrophages, lowers neuropathic-pain scores in small-fiber neuropathy models, accelerates corneal wound healing, reduces ischemia-reperfusion injury in renal and cardiac models, and improves glycemic control in type 2 diabetes preclinical models. The breadth of effect reflects the broad tissue distribution of the IRR under inflammatory conditions rather than a tissue-specific mechanism.<\/li>\n<\/ul>\n<p>The short plasma half-life (~2 minutes) combined with sustained biological effect (24\u201372 hours) means ARA-290 protocols typically use daily or every-other-day dosing despite the rapid molecular clearance \u2014 the pharmacodynamic duration is set by the downstream signalling cascade, not by plasma residence. Subcutaneous administration is the standard administration route and the route used in clinical development. <\/p>\n<h2>Published Evidence<\/h2>\n<p>ARA-290 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Diabetic neuropathy and small-fiber neuropathy studies<\/strong> \u2014 corneal nerve-fiber density assessment, intra-epidermal nerve-fiber density (IENFD), neuropathic-pain scoring; lead clinical studies indication, with Phase 2 trials in type 2 diabetic neuropathy showing improvement in nerve-fiber regeneration and pain scores<\/li>\n<li><strong>Neuropatia de fibras pequenas associada a sarcoidose<\/strong> \u2014 the indication for which ARA-290 holds US and EU orphan-drug designation; preclinical and Phase 2 studies in granulomatous inflammation models<\/li>\n<li><strong>Neuropathic pain studies<\/strong> \u2014 neuropatia perif\u00e9rica induzida por quimioterapia, neuropatia p\u00f3s-cir\u00fargica, dissec\u00e7\u00e3o mecanicista de vias de dor mediadas pelo IRR<\/li>\n<li><strong>Ischemia-reperfusion injury studies<\/strong> \u2014 modelos de isquemia-reperfus\u00e3o renal, card\u00edaca e cerebral; caracteriza\u00e7\u00e3o do efeito anti-apopt\u00f3tico e anti-inflamat\u00f3rio<\/li>\n<li><strong>Inflammation and innate immunity studies<\/strong> \u2014 polariza\u00e7\u00e3o de macr\u00f3fagos, ensaios de supress\u00e3o de citocinas, dissec\u00e7\u00e3o de sinaliza\u00e7\u00e3o dependente vs independente de IRR<\/li>\n<li><strong>Type 2 diabetes metabolic support<\/strong> \u2014 controlo glic\u00e9mico, preserva\u00e7\u00e3o de c\u00e9lulas beta, compara\u00e7\u00e3o com mecanismos de sensibiliza\u00e7\u00e3o \u00e0 insulina<\/li>\n<li><strong>Corneal wound-healing and ophthalmic studies<\/strong> \u2014 taxa de fecho de feridas epiteliais corneanas, regenera\u00e7\u00e3o de fibras nervosas na c\u00f3rnea (um dos tecidos mais densamente inervados e um marcador sens\u00edvel para repara\u00e7\u00e3o mediada por IRR)<\/li>\n<\/ul>\n<p>For broader context on related anti-inflammatory and tissue-repair peptides, see <a href=\"https:\/\/medsbase.com\/pt-pt\/bpc-157\/\">BPC-157<\/a> (repara\u00e7\u00e3o tecidual MSK\/GI derivada de pept\u00eddeos g\u00e1stricos), <a href=\"https:\/\/medsbase.com\/pt-pt\/tb-500\/\">TB-500<\/a> (fragmento de Timosina Beta-4, repara\u00e7\u00e3o tecidual ampla), e <a href=\"https:\/\/medsbase.com\/pt-pt\/kpv-lysine-proline-valine\/\">KPV<\/a> (tripept\u00eddeo anti-inflamat\u00f3rio derivado de \u03b1-MSH). Explore a gama completa <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para encontrar compostos relacionados. <\/p>\n<h2>For\u00e7as e Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<p>MedsBase stocks ARA-290 in 10 mg lyophilized vials calibrated to typical protocol lengths. Available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">For\u00e7a do frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos das embalagens<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 multi-week protocols across diabetic neuropathy, ischemia-reperfusion, corneal-repair, and inflammation models; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Clinical Phase 2 doses in published trials are 4 mg subcutaneous daily for diabetic neuropathy and sarcoidosis-associated neuropathy, so a single 10 mg pharmaceutical-grade vial represents a multi-day supply of clinical-equivalent dosing for in-vivo work. ARA-290 is supplied as the unmodified linear 11-mer \u2014 there is no acyl chain, no PEGylation, no disulfide bridge, and reconstitution is straightforward relative to longer or modified peptides. <\/p>\n<h2>Compara\u00e7\u00e3o \u2014 ARA-290 vs BPC-157<\/h2>\n<p>O ARA-290 e o <a href=\"https:\/\/medsbase.com\/pt-pt\/bpc-157\/\">BPC-157<\/a> are both used in tissue-repair and anti-inflammatory studies, but the two peptides target entirely different molecular machinery. ARA-290 is an EPO-derived innate-repair-receptor agonist that drives JAK2\/STAT3 cytoprotective signalling. BPC-157 is a 15-amino-acid synthetic stable gastric pentadecapeptide derived from a fragment of human gastric juice protein BPC, acting through a complex multi-pathway mechanism including nitric oxide synthase modulation, VEGF upregulation, and growth-factor-receptor cross-talk. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">ARA-290<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">BPC-157<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Origem<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">H\u00e9lice B da eritropoietina humana (HBSP)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Fragmento da prote\u00edna do suco g\u00e1strico humano BPC<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Comprimento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">11 amino\u00e1cidos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">15 amino\u00e1cidos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Recetor \/ alvo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Recetor de repara\u00e7\u00e3o inata (EPOR + \u03b2cR \/ CD131)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Vias m\u00faltiplas: sintase de NO, VEGF, intera\u00e7\u00e3o de fatores de crescimento<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Primary studies tissue<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nervo perif\u00e9rico, c\u00f3rnea, tecido isqu\u00e9mico, tecido inflamado<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Tend\u00e3o, ligamento, mucosa intestinal, m\u00fasculo<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efeito eritropoi\u00e9tico<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nenhum (caracter\u00edstica de design chave)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">N\/A (n\u00e3o \u00e9 um pept\u00eddeo da via EPO)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meia-vida plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2 minutos (o efeito persiste durante 24\u201372 horas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~30 minutos (biodisponibilidade oral alegada em pr\u00e9-cl\u00ednico)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Desenvolvimento cl\u00ednico<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Fase 2 (neuropatia diab\u00e9tica, SFN sarcoidose); designa\u00e7\u00e3o de medicamento \u00f3rf\u00e3o<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Apenas pr\u00e9-cl\u00ednico (sem ensaios cl\u00ednicos em reguladores principais)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Modifica\u00e7\u00e3o<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Pept\u00eddeo linear n\u00e3o modificado de 11 amino\u00e1cidos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Pept\u00eddeo linear n\u00e3o modificado de 15 amino\u00e1cidos (sal de acetato ou arginato est\u00e1vel)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on neuropathic-pain, peripheral-nerve regeneration, or IRR-mediated cytoprotection, ARA-290 is the targeted reference peptide. For studies focused on musculoskeletal tendon\/ligament repair or gastrointestinal mucosal healing, <a href=\"https:\/\/medsbase.com\/pt-pt\/bpc-157\/\">BPC-157<\/a> remains the more widely-studied option. The two peptides are sometimes combined in protocols that aim to recruit complementary repair pathways across both CNS\/peripheral-nerve tissue and connective tissue. See also <a href=\"https:\/\/medsbase.com\/pt-pt\/tb-500\/\">TB-500<\/a> (fragmento de Timosina Beta-4, refer\u00eancia ampla em repara\u00e7\u00e3o tecidual) e <a href=\"https:\/\/medsbase.com\/pt-pt\/kpv-lysine-proline-valine\/\">KPV<\/a> (tripept\u00eddeo anti-inflamat\u00f3rio derivado de \u03b1-MSH). <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Precisa de \u00e1gua BAC?<\/strong> A reconstitui\u00e7\u00e3o de qualquer frasco liofilizado requer \u00e1gua bacteriost\u00e1tica est\u00e9ril. Combine este produto com o nosso <a href=\"\/pt-pt\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 frasco multidose de 30 mL, conservado com 0,9% de \u00e1lcool benz\u00edlico, grau USP.<\/div>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene os frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para stock de trabalho a curto prazo. Para armazenamento a longo prazo sem abertura, congele a \u221220 \u00b0C. O ARA-290 liofilizado \u00e9 est\u00e1vel sob refrigera\u00e7\u00e3o at\u00e9 24 meses e a \u221220 \u00b0C at\u00e9 36 meses. Evite ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o no p\u00f3 liofilizado. O ARA-290 \u00e9 um pept\u00eddeo linear n\u00e3o modificado sem ponte dissulfeto ou cadeia acil, pelo que o manuseio \u00e9 simples em compara\u00e7\u00e3o com pept\u00eddeos estruturalmente complexos como o cagrilintida ou o semaglutida. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 10 mg vial, 2.0 mL of bacteriostatic water yields a 5 mg\/mL working concentration \u2014 0.08 mL delivers 400 mcg (a 1 mg dose requires 0.2 mL); 0.8 mL delivers a clinical-equivalent 4 mg dose. Swirl gently \u2014 do not shake vigorously, as foaming entrains air and can denature peptide chains. Allow the powder to dissolve fully (typically &lt;1 minute for ARA-290) before withdrawing. Once reconstituted, store the vial at 2\u20138 \u00b0C and use within 14\u201328 days. Protect from light. Discard if cloudiness, particulates, or colour change appears. <\/p>\n<h2>Perguntas Frequentes<\/h2>\n<h3>O ARA-290 \u00e9 um an\u00e1logo da EPO? Ele aumenta o hemat\u00f3crito?<\/h3>\n<p>O ARA-290 \u00e9 derivado da h\u00e9lice B da eritropoietina, mas foi projetado especificamente para <em>n\u00e3o<\/em> aumentar o hemat\u00f3crito. O efeito eritropoi\u00e9tico cl\u00e1ssico da EPO \u00e9 mediado pelo recetor de EPO homodim\u00e9rico (EPOR<sub>2<\/sub>) nos progenitores eritroides da medula \u00f3ssea. O ARA-290 liga-se ao recetor de repara\u00e7\u00e3o inata heterom\u00e9rico (EPOR + \u03b2cR\/CD131) e tem afinidade negligenci\u00e1vel pelo EPOR<sub>2<\/sub>. Ensaios cl\u00ednicos de Fase 2 publicados n\u00e3o mostram altera\u00e7\u00f5es na hemoglobina, hemat\u00f3crito ou contagem de reticul\u00f3citos ap\u00f3s doses repetidas. <\/p>\n<h3>O que \u00e9 o recetor de repara\u00e7\u00e3o inata (IRR)?<\/h3>\n<p>O recetor de repara\u00e7\u00e3o inata \u00e9 um heterocomplexo da subunidade do recetor de EPO (EPOR) e do recetor beta-comum (\u03b2cR, tamb\u00e9m conhecido como CD131 \u2014 a subunidade de sinaliza\u00e7\u00e3o partilhada pelos recetores de GM-CSF, IL-3 e IL-5). O IRR \u00e9 regulado positivamente localmente em tecidos stressados, lesionados ou inflamados, em vez de ser expresso constitutivamente, raz\u00e3o pela qual o ARA-290 atua como um sinal de repara\u00e7\u00e3o tecidual restrito ao contexto, em vez de um agonista sist\u00e9mico. <\/p>\n<h3>Por que o ARA-290 tamb\u00e9m \u00e9 chamado de cibinetida?<\/h3>\n<p>O ARA-290 \u00e9 o c\u00f3digo de desenvolvimento atribu\u00eddo pela Araim Pharmaceuticals (o desenvolvedor original). Cibinetida \u00e9 o nome n\u00e3o propriet\u00e1rio internacional (INN) atribu\u00eddo posteriormente para contextos de ensaios cl\u00ednicos e regulamentares. Os dois nomes referem-se ao mesmo pept\u00eddeo de 11 amino\u00e1cidos (CAS 1208243-50-8). <\/p>\n<h3>Por que a meia-vida plasm\u00e1tica \u00e9 t\u00e3o curta em rela\u00e7\u00e3o \u00e0 dura\u00e7\u00e3o do efeito?<\/h3>\n<p>O ARA-290 tem uma meia-vida plasm\u00e1tica de aproximadamente 2 minutos \u2014 o pept\u00eddeo \u00e9 rapidamente eliminado da circula\u00e7\u00e3o \u2014 mas o efeito biol\u00f3gico persiste por 24\u201372 horas atrav\u00e9s da ativa\u00e7\u00e3o a jusante das cascatas de sinaliza\u00e7\u00e3o JAK2\/STAT3, PI3K\/Akt e anti-apopt\u00f3ticas da fam\u00edlia Bcl-2. Este perfil farmacocin\u00e9tico \u00e9 t\u00edpico de pept\u00eddeos desencadeadores de recetores, onde a dura\u00e7\u00e3o \u00e9 definida pela cin\u00e9tica da cascata de sinaliza\u00e7\u00e3o e n\u00e3o por n\u00edveis plasm\u00e1ticos sustentados. <\/p>\n<h3>How does ARA-290 compare to BPC-157 for tissue repair studies?<\/h3>\n<p>Both peptides are used in tissue-repair studies but target different machinery and different tissues. ARA-290 acts via the innate repair receptor (EPOR + CD131) and is best-characterised in peripheral-nerve, corneal, and ischemic-tissue studies. <a href=\"https:\/\/medsbase.com\/pt-pt\/bpc-157\/\">BPC-157<\/a> acts through a multi-pathway mechanism involving nitric oxide synthase modulation and VEGF upregulation, and is best-characterised in tendon, ligament, gut mucosal, and muscle studies. Some protocols combine the two peptides to recruit complementary repair pathways. <\/p>\n<h3>O que \u00e9 a neuropatia de pequenas fibras associada \u00e0 sarcoidose e por que \u00e9 que o ARA-290 tem designa\u00e7\u00e3o de medicamento \u00f3rf\u00e3o para esta condi\u00e7\u00e3o?<\/h3>\n<p>Sarcoidosis is a granulomatous inflammatory disease that produces a debilitating small-fiber neuropathy (SFN) in a substantial fraction of affected patients. ARA-290 holds US FDA and EU EMA orphan-drug designation for sarcoidosis-associated SFN, reflecting the rarity of the indication and the absence of other targeted treatments. The orphan designation supports clinical studies but does not constitute approval \u2014 ARA-290 is investigational at the time of this writing. <\/p>\n<h3>What is the standard dose for ARA-290?<\/h3>\n<p>Published Phase 2 clinical trials have used 2\u20134 mg subcutaneous daily for diabetic neuropathy and sarcoidosis-associated SFN. Preclinical animal studies have used wider dose ranges depending on model and tissue. Users should determine dose ranges from peer-reviewed literature appropriate to their specific protocol. <\/p>\n<h3>O ARA-290 requer manuseamento especial devido \u00e0s modifica\u00e7\u00f5es de dissulfureto ou acil?<\/h3>\n<p>N\u00e3o. O ARA-290 \u00e9 um p\u00e9ptido linear de 11 amino\u00e1cidos n\u00e3o modificado, sem ponte de dissulfureto, sem acila\u00e7\u00e3o com \u00e1cido gordo e sem PEGila\u00e7\u00e3o. A reconstitui\u00e7\u00e3o e o manuseamento s\u00e3o simples \u2014 uma agita\u00e7\u00e3o suave dissolve o p\u00f3 liofilizado em ~1 minuto. Compare isto com p\u00e9ptidos estruturalmente complexos como o cagrilintida (cadeia acil + dissulfureto), o semaglutida (cadeia acil) ou p\u00e9ptidos da classe da insulina, onde a reconstitui\u00e7\u00e3o requer um tempo de equil\u00edbrio mais longo. <!-- medsbase-related-alts-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Pept\u00eddeo n\u00e3o eritropoi\u00e9tico derivado da EPO com 11 amino\u00e1cidos<br \/>\n\u2705 Agonista do recetor de repara\u00e7\u00e3o inata (EPOR + CD131)<br \/>\n\u2705 Sinaliza\u00e7\u00e3o anti-inflamat\u00f3ria, neuroprotetora e de repara\u00e7\u00e3o tecidual<br \/>\n\u2705 Sem eleva\u00e7\u00e3o do hemat\u00f3crito (caracter\u00edstica chave de design vs EPO completa)<br \/>\n\u2705 Designado como medicamento \u00f3rf\u00e3o para neuropatia de pequenas fibras associada \u00e0 sarcoidose<\/p>\n<p><strong>ARA-290<\/strong> cont\u00e9m composto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":71396,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6461,6462,5441],"class_list":["post-71388","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-ara-290","product_tag-cibinetide","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product\/71388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=71388"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media\/71396"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=71388"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_brand?post=71388"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_cat?post=71388"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_tag?post=71388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}